The Counterparty’s Playbook
How Acquirers, Investors, and Institutions Think
The learning framework
The number that was never the offer
A founder receives an offer and reads the headline figure. It is larger than anything discussed internally, and the reaction in the room is relief. The acquirer's corporate development team did not arrive at that figure by valuing the company. They started from what the asset is worth inside their organization, which is higher than its standalone value and is the reason the conversation is happening at all. No acquirer buys something worth less to them than it is to you. Then they subtracted twice: once for the risks they inherit, and once for the room they intend to keep for the negotiation. So the offer is not their number. It is their number less what they expect to concede, and nothing in the document tells the founder how large that second subtraction is. The structure compounds it. A portion is contingent on milestones the acquirer will control after closing. A portion is held back against representations the founder will make. A portion is denominated in equity of the acquirer rather than in cash. The founder negotiates the headline figure up. The acquirer concedes, because the headline was never where the value sat. The structure it sat in was agreed to without discussion, by a founder who had never been shown that the structure was the negotiation.
Why founders read the wrong side of the deal
Founders spend years learning their technology, their market, and their clinical evidence. Almost none of that transfers to reading a counterparty. So the acquirer's behavior gets interpreted through the founder's own frame: enthusiasm means they want it, delay means they are busy, a lowball means they do not understand the science. Usually none of those readings is correct. Corporate development is running a process with internal approvals, competing candidate deals, a budget cycle, and a set of people whose incentives differ from one another. The person championing your deal internally is solving a different problem from the person who signs off on it. The same misreading applies at the term level. An earnout is not a compliment about your future performance. It is a mechanism for transferring risk about an outcome the acquirer is uncertain of, and after closing they will control most of the levers that determine whether it pays. A holdback is not a formality. Both are priced, and both are negotiable, and neither is usually negotiated because the founder is still looking at the headline.
Reading the deal you are being offered
Healthcare innovators who complete this evolution can state what the acquirer is actually buying, which is rarely the same as what the founder thinks they built. They understand how the offer was constructed and which components carry the real value. They know what diligence will look for and have resolved what they can before it starts, because a defect found by the other side is leverage and the same defect found early is administrative. They can distinguish a structural term from a negotiating position, and they know which items on a term sheet the acquirer expects to concede. They also understand who inside the acquirer wants the deal and who has to approve it, and that those are different people with different concerns.
By the end of this evolution, you will be able to:
Understand what the acquirer is actually buying
Separate the technology from the asset. Acquirers buy a regulatory position, a clinical dataset, a manufacturing capability, an installed base, a team, or a defensive block against a competitor. Learn to identify which of these you represent, because it determines who will pay the most and what they will pay for.
Read the offer, and estimate the number behind it
Work backward from a headline figure to the model that produced it. Understand that the offer is not the acquirer's own number: they begin from what the asset is worth inside their organization, which must exceed your standalone value or there would be no rationale for a transaction, then subtract the risks they inherit and the room they intend to keep. Learn to estimate that internal figure from what you can observe: gaps in their portfolio, holes in their pipeline, sales infrastructure that your product would fill, competitive exposure, and what they have paid for comparable assets. The estimate will be imprecise, because their strategic rationale is rarely disclosed and sometimes not fully agreed internally. Negotiating without one means negotiating against their figure alone.
Price an earnout, a holdback, and a milestone
Understand these as risk-transfer instruments rather than as compliments or formalities. Learn who controls the levers after closing, how contingent consideration is valued and how often it pays, and which provisions determine whether an earnout is achievable or decorative.
Prepare for diligence before it begins
Learn what corporate development and their counsel actually examine: chain of title, assignment gaps, regulatory correspondence, clinical data integrity, quality systems, third-party agreements, and change-of-control provisions. Resolve what you can while it is still administrative.
Read the acquirer as an organization
Identify the internal champion, the approver, and the skeptic, and understand that each is solving a different problem. Learn how corporate development processes work, why deals stall for reasons unrelated to your company, and what a delay usually means.
Distinguish structural terms from negotiating positions
Recognize which provisions an acquirer will not move on because of internal policy or precedent, and which are opening positions they expect to concede. Learn where founders typically spend their leverage and where it would have been worth more.
See the exit from the investor's side of the table
Understand that your investors have a fund life, a return threshold, and a preference stack that shape which offers they will support and when. Learn why an investor may favor a deal that is worse for you, and how governance determines whose preference prevails.
Position the company before the conversation starts
Understand what makes an asset easy to acquire: clean title, transferable agreements, documented systems, and a regulatory position that survives change of control. Learn why this work has to be done years before an approach, not after one.
Why this matters
Recommended for
Healthcare innovators navigating:
Faculty who understand the process move through it faster.
Academic medical centers, research universities, and health systems sponsor cohorts so that inventors arrive at the office of technology transfer prepared: complete disclosures, clean assignment records, and realistic expectations about pathway and timeline. Cohort training is available for faculty, residents, and research staff, with CME.
Learn more about institutional cohorts →How to get started
Your path to becoming a Certified Professional Entrepreneur
Reserve your seat
Your deposit reserves a place in the cohort. Twenty seats. No application, no admissions committee, no waiting on a decision.
Begin the evolutions
Structured online learning you work through on your own schedule. Lectures run under fifteen minutes. Each evolution carries reading, supporting material, working tools, and case studies drawn from real transactions.
Join the live sessions
Live discussion sessions on Zoom, facilitated by Chris and Christos. Not recorded. This is where the material meets your actual situation, and where the cohort becomes a network.
Continue your structural training
Answers that help you decide with confidence
Only one side of the table has done this before.